{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:58:18Z","timestamp":1772121498303,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Haplo-fever (HF) is a form of non-infectious fever that occurs shortly after haploidentical (HID) hematopoietic stem cell transplantation (HSCT). Its clinical significance, risk factors, and pathophysiology, particularly in the context of anti-thymocyte globulin (ATG)-based prophylaxis for graft-versus-host disease (GvHD), remain largely unknown. Here, we retrospectively analyzed clinical data from 143 consecutive HID HSCT recipients. Patients with HF exhibited a higher incidence of chronic GvHD, a lower risk of measurable residual disease recurrence, and improved event-free survival, particularly among those receiving ATG-based acute GvHD prophylaxis. Identified risk factors for HF included higher infused doses of CD34\n                    <jats:sup>+<\/jats:sup>\n                    cells, mononucleated cells, CD3\n                    <jats:sup>+<\/jats:sup>\n                    T cells, and CD4\n                    <jats:sup>+<\/jats:sup>\n                    memory T cells. At 90 days post-transplant, patients with HF demonstrated elevated absolute numbers of CD4\n                    <jats:sup>+<\/jats:sup>\n                    memory T cells and activated CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. RNA sequencing of peripheral blood CD3\n                    <jats:sup>+<\/jats:sup>\n                    T cells at day 2 post-transplant revealed transcriptional signatures of T-cell activation and an abundance of activated CD4\n                    <jats:sup>+<\/jats:sup>\n                    memory T cells as hallmarks of HF. Using multiple complementary approaches, we demonstrated the impact of HF on transplant outcomes, identified its risk factors, and elucidated the underlying cellular and molecular mechanisms.\n                  <\/jats:p>","DOI":"10.1097\/bs9.0000000000000280","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:00:12Z","timestamp":1772118012000},"page":"e00280","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Anti-thymocyte globulin-resistant CD4+ memory T cells contribute to haplo-fever after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1097","volume":"8","author":[{"given":"Huihong","family":"Huang","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Lu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Duan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingtao","family":"Huang","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"},{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Gu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengkai","family":"Pan","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"},{"name":"Collaborative Innovation Center of Hematology, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"R1-20260226","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.2023021336","article-title":"TCR\u03b1\u03b2\/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.","volume":"143","author":"Merli","year":"2023","journal-title":"Blood"},{"key":"R2-20260226","article-title":"Comparison of autologous, matched sibling, and alternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: a propensity score matching study.","author":"Wang","year":"2023","journal-title":"Hematol Oncol"},{"issue":"6","key":"R3-20260226","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3324\/haematol.2020.247296","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia.","volume":"106","author":"Nagler","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"R4-20260226","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.bbmt.2018.06.004","article-title":"Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes.","volume":"24","author":"McCurdy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"R5-20260226","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/s41409-019-0522-4","article-title":"Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes.","volume":"54","author":"Solh","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"R6-20260226","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"R7-20260226","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/petr.12586","article-title":"Infusion-related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graft-versus-host disease.","volume":"19","author":"Chen","year":"2015","journal-title":"Pediatr Transplant"},{"issue":"4","key":"R8-20260226","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbmt.2011.08.018","article-title":"Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.","volume":"18","author":"Jacobson","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"R9-20260226","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2018.04.010","article-title":"Peripheral blood grafts for T cell\u2013replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome.","volume":"24","author":"Raj","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"R10-20260226","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation.","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"R11-20260226","doi-asserted-by":"crossref","first-page":"111.e1","DOI":"10.1016\/j.jtct.2021.11.012","article-title":"Cytokine release syndrome following peripheral blood stem cell haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide.","volume":"28","author":"Otoukesh","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R12-20260226","doi-asserted-by":"crossref","first-page":"820591","DOI":"10.3389\/fmed.2022.820591","article-title":"Clinical significance of haplo-fever and cytokine profiling after graft infusion in allogeneic stem cell transplantation from haplo-identical donors.","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"R13-20260226","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated.","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"R14-20260226","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","article-title":"Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.","volume":"20","author":"Raj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"R15-20260226","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"15","key":"R16-20260226","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"4","key":"R17-20260226","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00277-018-3584-2","article-title":"Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years.","volume":"98","author":"Zhang","year":"2019","journal-title":"Ann Hematol"},{"issue":"8","key":"R18-20260226","doi-asserted-by":"crossref","first-page":"512.e1","DOI":"10.1016\/j.jtct.2023.05.017","article-title":"Low incidence of relapse with a moderate conditioning regimen of fludarabine, busulfan, and melphalan for patients with myeloid malignancies: a single-center analysis of 100 patients.","volume":"29","author":"Jiang","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"R19-20260226","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"24","key":"R20-20260226","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","article-title":"Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial.","volume":"66","author":"Wang","year":"2021","journal-title":"Sci Bull"},{"issue":"6","key":"R21-20260226","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41409-022-01639-0","article-title":"Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial.","volume":"57","author":"Wang","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R22-20260226","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2018.08.030","article-title":"The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"issue":"11","key":"R23-20260226","first-page":"889","article-title":"[Chinese consensus on minimal residual disease detection and interpretation of patients with acute myeloid leukemia (2021)].","volume":"42","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"10","key":"R24-20260226","first-page":"846","article-title":"[The consensus of allogeneic hematopoietic transplantation for hematological diseases in China(2016)\u2014post-transplant leukemia relapse].","volume":"37","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"R25-20260226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","article-title":"Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.","volume":"10","author":"Chang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"1","key":"R26-20260226","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1182\/hematology.2021000224","article-title":"MRD in adult Ph\/BCR-ABL-negative ALL: how best to eradicate?","volume":"2021","author":"G\u00f6kbuget","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"R27-20260226","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.2021013054","article-title":"Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning.","volume":"139","author":"McCurdy","year":"2022","journal-title":"Blood"},{"issue":"2","key":"R28-20260226","doi-asserted-by":"crossref","first-page":"e00183","DOI":"10.1097\/BS9.0000000000000183","article-title":"COVID-19 in immunocompromised patients after hematopoietic stem cell transplantation: a pilot study.","volume":"6","author":"Zhang","year":"2024","journal-title":"Blood Sci"},{"key":"R29-20260226","article-title":"Cytokines induced by antithymocyte globulin in transplant conditioning and associated infusional side effects.","author":"Storek","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"R30-20260226","doi-asserted-by":"crossref","first-page":"921293","DOI":"10.3389\/fimmu.2022.921293","article-title":"Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia.","volume":"13","author":"Barkhordar","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"R31-20260226","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s44313-024-00049-z","article-title":"Post-transplant cyclophosphamide plus anti-thymocyte globulin decreased serum IL-6 levels when compared with post-transplant cyclophosphamide alone after haploidentical hematopoietic stem cell transplantation.","volume":"60","author":"Koh","year":"2025","journal-title":"Blood Res"},{"issue":"2","key":"R32-20260226","doi-asserted-by":"crossref","first-page":"101634","DOI":"10.1016\/j.beha.2025.101634","article-title":"Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions.","volume":"38","author":"Fu","year":"2025","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"R33-20260226","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2007-08-109678","article-title":"Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.","volume":"111","author":"Zheng","year":"2008","journal-title":"Blood"},{"issue":"7","key":"R34-20260226","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"R35-20260226","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2172-13-70","article-title":"Anti-thymocyte globulin (ATG) differentially depletes na\u00efve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice.","volume":"13","author":"Xia","year":"2012","journal-title":"BMC Immunol"},{"issue":"2","key":"R36-20260226","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ajt.16263","article-title":"Relationship between antithymocyte globulin, T cell phenotypes, and clinical outcomes in pediatric kidney transplantation.","volume":"21","author":"Shaw","year":"2021","journal-title":"Am J Transplant"},{"issue":"10","key":"R37-20260226","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1097\/TP.0000000000003169","article-title":"Memory T cells in transplantation: old challenges define new directions.","volume":"104","author":"Nicosia","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"R38-20260226","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","article-title":"Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.","volume":"5","author":"Pearl","year":"2005","journal-title":"Am J Transplant"},{"issue":"7","key":"R39-20260226","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"R40-20260226","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes.","volume":"36","author":"Ross","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"R41-20260226","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer.","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat Rev Immunol"}],"container-title":["Blood Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:00:16Z","timestamp":1772118016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bs9.0000000000000280","relation":{},"ISSN":["2543-6368"],"issn-type":[{"value":"2543-6368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"2025-07-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}